pre 084 has been researched along with oxidopamine in 3 studies
| Studies (pre 084) | Trials (pre 084) | Recent Studies (post-2010) (pre 084) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 116 | 0 | 73 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | pre 084 (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bez, F; Cenci, MA; Francardo, V; Nissbrandt, H; Ruscher, K; Wieloch, T | 1 |
| Kadnikov, IA; Seredenin, SB; Voronin, MV; Voronkov, DN | 1 |
| Cao, T; Guo, CH; Waddington, JL; Zhen, XC; Zheng, LT | 1 |
3 other study(ies) available for pre 084 and oxidopamine
| Article | Year |
|---|---|
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Exploratory Behavior; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Receptors, sigma; Serotonin; Sigma-1 Receptor | 2014 |
Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Benzimidazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Ethylenediamines; Male; Mice; Mice, Inbred ICR; Morpholines; Neurons; Neuroprotection; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Receptors, sigma; Rotarod Performance Test; Sigma-1 Receptor; Substantia Nigra | 2019 |
Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; DEAD-box RNA Helicases; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Flavonols; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Morpholines; Oxidopamine; Parkinson Disease; Receptors, sigma; Ribonuclease III; Sigma-1 Receptor; Tamoxifen | 2020 |